Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Whitehawk Therapeutics (WHWK) Net Income towards Common Stockholders (2018 - 2025)

Historic Net Income towards Common Stockholders for Whitehawk Therapeutics (WHWK) over the last 8 years, with Q3 2025 value amounting to -$17.7 million.

  • Whitehawk Therapeutics' Net Income towards Common Stockholders fell 4106.02% to -$17.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$103.2 million, marking a year-over-year decrease of 6725.19%. This contributed to the annual value of -$63.7 million for FY2024, which is 315.37% up from last year.
  • Whitehawk Therapeutics' Net Income towards Common Stockholders amounted to -$17.7 million in Q3 2025, which was down 4106.02% from -$52.8 million recorded in Q2 2025.
  • Over the past 5 years, Whitehawk Therapeutics' Net Income towards Common Stockholders peaked at -$1.5 million during Q2 2021, and registered a low of -$87.1 million during Q3 2021.
  • Moreover, its 5-year median value for Net Income towards Common Stockholders was -$16.0 million (2021), whereas its average is -$20.3 million.
  • In the last 5 years, Whitehawk Therapeutics' Net Income towards Common Stockholders tumbled by 291134.16% in 2021 and then skyrocketed by 8338.0% in 2022.
  • Whitehawk Therapeutics' Net Income towards Common Stockholders (Quarter) stood at -$16.0 million in 2021, then grew by 12.99% to -$13.9 million in 2022, then dropped by 16.93% to -$16.3 million in 2023, then dropped by 12.32% to -$18.3 million in 2024, then grew by 3.16% to -$17.7 million in 2025.
  • Its Net Income towards Common Stockholders stands at -$17.7 million for Q3 2025, versus -$52.8 million for Q2 2025 and -$14.4 million for Q1 2025.